RenovoRx, Inc.
RNXT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -25,511.6% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -20,497.7% | – | – | – |
| EPS Diluted | -0.37 | -0.5 | -0.54 | -0.4 |
| % Growth | 26% | 7.4% | -35% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |